Noninvasive continuous hemodynamic monitoring

ClearSight finger cuff on HemoSphere advanced monitoring platform
The ClearSight system is a noninvasive solution that enables clinical decision support to help optimize patient perfusion.

The ClearSight system provides continuous blood pressure and advanced hemodynamic parameters from a noninvasive finger cuff. Continuous data offered by the validated ClearSight system enables you to proactively optimize perfusion through hemodynamic management.

Extend the benefits of hemodynamic monitoring
The ClearSight system gives you noninvasive access to beat-to-beat hemodynamic information for a broad patient population, including patients in whom an arterial line would not be typically be placed.

Proactive decision support for individualized patient care
Noninvasive hemodynamic monitoring offered by the ClearSight system provides information to enable you to make proactive clinical decisions across the continuum of care, including moderate- to high-risk surgery patients and can be utilized to manage your patients’ changing clinical situations in surgical, as well as acute care settings.

A versatile approach to continuous monitoring
The ClearSight system connects to your patient’s finger. Upon starting a measurement, the finger cuff can be used and re-applied for up to 72 hours on one patient. Two ClearSight finger cuffs may be connected simultaneously to alternate the measurement between two fingers. This allows uninterrupted continuous monitoring.

Advanced hemodynamic parameters
• Cardiac output (CO)
• Stroke volume (SV)
• Stroke volume variation (SVV)
• Systemic vascular resistance (SVR)
• Mean arterial pressure (MAP)

Heart Reference Sensor
The ClearSight system Heart Reference Sensor (HRS) compensates for hydrostatic pressure changes due to height differences between finger and heart. The HRS compensates for clinician repositioning of the patient’s hand during a procedure or for patient movement.

Noninvasive hemodynamic monitoring provides proactive patient insights for individualized patient management.

Hemodynamic instability
The ClearSight system offers a noninvasive approach to monitoring key hemodynamic parameters, including: stroke volume (SV), stroke volume variation (SVV), cardiac output (CO), systemic vascular resistance (SVR), mean arterial pressure (MAP). Continuous access to pressure and flow parameters allow you to evaluate hemodynamic instability and guide appropriate treatment.

Hypotension
Cleveland Clinic researchers showed that continuous noninvasive monitoring reduced the amount of intraoperative hypotension (IOH) by nearly half when compared to intermittent blood pressure monitoring. Early detection of hypotension by continuous hemodynamic monitoring allows for timely remedial actions, thereby reducing intraoperative hypotension. Clarity through advanced hemodynamic parameters CO, SV, SVV, and SVR can help you determine if the cause of IOH is preload, afterload, or contractility.

Sepsis management
Access to CO and SV enables early detection and management of sepsis which is critical to improving survival rates and reducing the economic burden of sepsis. The noninvasive ClearSight system allows continuous assessment of your patient’s physiological needs and helps you recognize hemodynamic instability from sepsis. The ClearSight finger cuff can be used to measure flow-based parameters continuously prior to, during, and after the fluid administration portion of 3-hour and 6-hour CMS sepsis bundles.
The ClearSight system provides continuous blood pressure and advanced hemodynamic parameters from a noninvasive finger cuff. Continuous data offered by the validated ClearSight system enables you to proactively optimize perfusion through hemodynamic management.

Extend the benefits of hemodynamic monitoring
The ClearSight system gives you noninvasive access to beat-to-beat hemodynamic information for a broad patient population, including patients in whom an arterial line would not be typically placed.1

Proactive decision support for individualized patient care
Noninvasive hemodynamic monitoring offered by the ClearSight system provides information to enable you to make proactive clinical decisions across the continuum of care, including moderate- to high-risk surgery patients and can be utilized to manage your patients’ changing clinical situations in surgical, as well as acute care settings.

A versatile approach to continuous monitoring
The ClearSight system connects to your patient’s finger. Upon starting a measurement, the finger cuff can be used and re-applied for up to 72 hours on one patient. Two ClearSight finger cuffs may be connected simultaneously to alternate the measurement between two fingers. This allows uninterrupted continuous monitoring.

Heart Reference Sensor
The ClearSight system Heart Reference Sensor (HRS) compensates for hydrostatic pressure changes due to height differences between finger and heart. The HRS compensates for clinician repositioning of the patient’s hand during a procedure or for patient movement.

Advanced hemodynamic parameters
• Cardiac output (CO)
• Stroke volume (SV)
• Stroke volume variation (SVV)
• Systemic vascular resistance (SVR)
• Mean arterial pressure (MAP)

Noninvasive hemodynamic monitoring
Noninvasive hemodynamic monitoring provides proactive patient insights for individualized patient management.

Hemodynamic instability
The ClearSight system offers a noninvasive approach to monitoring key hemodynamic parameters, including: stroke volume (SV), stroke volume variation (SVV), cardiac output (CO), systemic vascular resistance (SVR), mean arterial pressure (MAP). Continuous access to pressure and flow parameters allow you to evaluate hemodynamic instability and guide appropriate treatment.

Hypotension
Cleveland Clinic researchers showed that continuous noninvasive monitoring reduced the amount of intraoperative hypotension (IOH) by nearly half when compared to intermittent blood pressure monitoring.2 Early detection of hypotension by continuous hemodynamic monitoring allows for timely remedial actions, thereby reducing intraoperative hypotension.2

Sepsis management
Access to CO and SV enables early detection and management of sepsis which is critical to improving survival rates and reducing the economic burden of sepsis. The noninvasive ClearSight system allows continuous assessment of your patient’s physiological needs and helps you recognize hemodynamic instability from sepsis.3 The ClearSight finger cuff can be used to measure flow-based parameters continuously prior to, during, and after the fluid administration portion of 3-hour and 6-hour CMS sepsis bundles.
ClearSight system

The ClearSight system is comprised of the ClearSight finger cuff and HemoSphere advanced monitoring platform

1. HemoSphere advanced monitor
2. ClearSight module
3. Pressure controller
4. Heart reference sensor
5. ClearSight finger cuffs

<table>
<thead>
<tr>
<th>Description</th>
<th>Model</th>
</tr>
</thead>
<tbody>
<tr>
<td>ClearSight finger cuff small multi pack</td>
<td>CSCS</td>
</tr>
<tr>
<td>ClearSight finger cuff medium multi pack</td>
<td>CSCM</td>
</tr>
<tr>
<td>ClearSight finger cuff large multi pack</td>
<td>CSCL</td>
</tr>
<tr>
<td>HemoSphere ClearSight upgrade</td>
<td>HEMCSMUPG</td>
</tr>
<tr>
<td>HemoSphere smart recovery non-cardiac bundle</td>
<td>HEMPCSR2</td>
</tr>
</tbody>
</table>

Know more. Know now.
Visit edwards.com or contact your Edwards representative

For more than 50 years, Edwards Lifesciences has been helping you make proactive clinical decisions and advance the care of surgical and acutely ill patients across the continuum of care. Through ongoing collaboration with clinicians, providing continuous education, and our dedication to purposeful innovation, Edwards continues to develop smart hemodynamic management solutions that enable proactive decision support.

References

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, ClearSight, and HemoSphere are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP--EU-1698 v1.0
Edwards Lifesciences • Route de L’Etraz 70, 1260 Nyon, Switzerland • edwards.com